AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03755999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The premature infant oral motor intervention (PIOMI)
Description: The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
Study NCT01059006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PresbyLASIK
Description: PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
Study NCT03151122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Continuous Support
Description: The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age.
Study NCT03151122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine follow-up care
Description: after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
Study NCT00524888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suturing laceration
Description: suturing simple lacerations of the hand
Study NCT00524888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bioadhesive
Description: using bioadhesive on simple lacerations of the hand
Study NCT03112291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apexification
Description: Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
Study NCT00335309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Irrigation
Description: Twice a day irrigation with 100cc saline for 4 days
Study NCT00335309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Amoxicillin and Clavulanate acid
Description: IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
Study NCT02638714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Intervention: Transplantation of autologous purified stem cells
Study NCT00830804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg tablet taken orally twice daily
Study NCT01719848 — intervention group
Intervention type: OTHER
Intervention: Measurements of parameters related with physical examinations for difficult airway prediction
Study NCT04298294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin
Description: biologic activator
Study NCT04845594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MySmileBuddy (MSB)
Description: The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
Study NCT00560092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal magnesium sulfate
Description: intrathecal magnesium sulfate
Study NCT00413660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 4 blinded tablets administered BID
Study NCT00830804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir
Description: 800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
Study NCT02907086 — intervention group
Intervention type: OTHER
Intervention: blood collection
Description: Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
Study NCT01035008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Description: The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
Study NCT01809678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Once weekly program of cognitive-behavioral therapy for smoking cessation
Study NCT01809678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Once weekly program of cognitive-behavioral therapy for smoking cessation
Study NCT01809678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Twice weekly program of 1-hour Iyengar yoga classes
Study NCT01809678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Twice weekly program of 1-hour wellness classes on a variety of health topics.
Study NCT00686010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, 3 tablets, oral, once daily after breakfast
Study NCT00686010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 300mg
Description: JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
Study NCT00686010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 600mg
Description: JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
Study NCT00686010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 900mg
Description: JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
Study NCT03515213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 145mg of fenofibrate
Study NCT03515213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03466112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance training
Description: endurance training with stationary bicycles
Study NCT00413660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets
Study NCT00413660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT03896477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumosil
Description: One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
Study NCT03896477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
Study NCT03896477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
Study NCT01179308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General-epidural anesthesia
Description: General anesthesia combined with epidural anesthesia
Study NCT01179308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced general anesthesia and postoperative opioids
Description: General anesthesia alone
Study NCT04716608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy program
Description: physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program.
Study NCT04716608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care treatment
Description: stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
Study NCT01138085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor
Study NCT01138085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: AKT Inhibitor
Study NCT04169178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX55
Description: A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
Study NCT05113654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
Study NCT03632707 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic Resonance Imaging of the knee
Description: After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
Study NCT03632707 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Knee Arthroscopy
Description: Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
Study NCT01166217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state.
Study NCT02342769 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir/Abacavir/Lamivudin
Description: Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
Study NCT03466112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance and tone program
Description: flexibility, core strength, balance, relaxation
Study NCT01616212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy /Adol and PW for parents
Description: Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
Study NCT01616212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy for adolescents
Description: Motivational Enhancement Therapy for adolescents
Study NCT01616212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Education for adolescents, Parenting Wisely for parents
Description: Drug Education for adolescents, Parenting Wisely for parents
Study NCT01616212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Education for adolescents
Description: Drug Education for adolescents
Study NCT01792297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Study NCT01792297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Study NCT00375427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
Study NCT03782623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of eicosanoid profile prior to and after PRBC transfusion
Description: Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
Study NCT04011735 — intervention group
Intervention type: DRUG
Intervention: Respimat
Description: Soft Mist Inhaler product
Study NCT02633046 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acthar Gel
Description: Acthar Gel 80 U/mL solution for subcutaneous injection
Study NCT03073343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betaine (trimethyglycine)
Description: Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
Study NCT00602511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity
Study NCT00602511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity
Study NCT01100645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sominex
Description: Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
Study NCT01100645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient
Study NCT04277832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionary
Description: All patients will answer two different questionary (TUPAST, TOPAS 2)
Study NCT02142504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
Study NCT02142504 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
Study NCT02142504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Placebo-matching norovirus bivalent VLP vaccine
Study NCT03904784 — intervention group
Intervention type: BEHAVIORAL
Intervention: school withdrawal teenagers
Description: The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
Study NCT02923310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets Rich Plasma
Study NCT02923310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leucocyte - Platelets Rich Plasma
Study NCT02923310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hialuronic Acid
Study NCT00617591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg orally on days 1-21
Study NCT00617591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: 40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)
Study NCT00617591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally on days on 1-4
Study NCT02854007 — intervention group
Intervention type: DEVICE
Intervention: Coronary angioplasty with implant of bioresorbable device
Description: Percutaneous coronary intervention
Study NCT00605072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
Study NCT00605072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
Study NCT00605072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
Study NCT00605072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine, long acting
Description: If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
Study NCT00605072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol, long-acting
Description: If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
Study NCT03372564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip Capsule Repair
Description: In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
Study NCT01875705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: Escalating doses of GDC-0994 until maximum tolerated dose is reached
Study NCT01309932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Study NCT01227226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears
Description: Instill one drop of artificial tears
Study NCT04519034 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: There will be no intervention
Study NCT03947671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapr Rounds Hyper/Hypothermia Wraps
Description: Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
Study NCT03947671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be administered as it would be per standard of care
Study NCT03947671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be administered as it would be per standard of care
Study NCT01875705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
Study NCT03275428 — intervention group
Intervention type: DEVICE
Intervention: transnasal humidified rapid-insufflation ventilator exchange
Description: high flow nasal cannula with humidified oxygen
Study NCT00425100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: probe
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: probe
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: probe
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: probe
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: probe
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: probe
Study NCT02361619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: perpetrator
Study NCT01309932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Study NCT01240213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 2000 IU per day of Vitamin D
Study NCT01240213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Placebo per day
Study NCT02688426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-Level Laser Therapy (Sham LLLT)
Description: perform with the machine off
Study NCT02688426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Low-Level Laser Therapy (Sham LLLT)
Description: perform with the machine off
Study NCT02688426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 6J Low-Level Laser Therapy (6J LLLT)
Description: irradiation will be perform with 6J